New combo aims to boost lung cancer treatment
NCT ID NCT06644768
First seen Oct 31, 2025 · Last updated Jun 20, 2026 · Updated 36 times
Summary
This study tests whether adding valemetostat to the standard immunotherapy pembrolizumab works better than pembrolizumab alone for people with advanced non-small cell lung cancer that has high PD-L1 levels. About 137 adults who have not had prior treatment will participate. The goal is to see if the combination can delay cancer growth and improve response rates.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
BRCR Global
RECRUITINGPlantation, Florida, 33322-5426, United States
-
CINPAM Centro Integrado De Pesquisa Da Amazonia
RECRUITINGManaus, 69005-080, Brazil
-
California Research Institute
RECRUITINGLos Angeles, California, 90027, United States
-
Cancer Institute Hospital of JFCR
RECRUITINGKōtoku, 135-8550, Japan
-
Centro de Investigacion Pergamino Sa
NOT_YET_RECRUITINGPergamino, B2700CPM, Argentina
-
Centro de Pesquisas Clinica Reichow
RECRUITINGBlumenau, 89010-340, Brazil
-
Cepho - Centro de Estudos E Pesquisas de Hematologia E Oncologia
NOT_YET_RECRUITINGSanto André, 09060-650, Brazil
-
Chengdu Shang Jin Nan Fu Hospital
NOT_YET_RECRUITINGChengdu, 611730, China
-
Clinica Viedma S.A.
RECRUITINGViedma, R8500ACE, Argentina
-
Clínica de Neoplasias Litoral Ltda.
NOT_YET_RECRUITINGItajaĂ-, 88301-220, Brazil
-
Columbia University Irving Medical Center
NOT_YET_RECRUITINGNew York, New York, 10032, United States
-
Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto
RECRUITINGSao Jose Rio Preto, 15090-000, Brazil
-
Fundacion Ars Medica
NOT_YET_RECRUITINGN Salvador de Jujuy, 4600, Argentina
-
Harbin Medical University Cancer Hospital
RECRUITINGHarbin, 150081, China
-
Henan Cancer Hospital
RECRUITINGZhengzhou, 450003, China
-
Hospital Italiano de Buenos Aires
RECRUITINGBuenos Aires, 1199, Argentina
-
Hospital Nossa Senhora da Conceicao
RECRUITINGPorto Alegre, 91350-280, Brazil
-
Instituto Alexander Fleming
RECRUITINGBuenos Aires, 1426, Argentina
-
Instituto Medico de La Fundacion Estudios Clinicos
NOT_YET_RECRUITINGRosario, 2000, Argentina
-
Jiamusi Cancer Hospital
RECRUITINGJiamusi, 154007, China
-
Jilin Cancer Hospital
RECRUITINGChangchun, 130000, China
-
Kitasato University Hospital
RECRUITINGSagamihara-shi, 252-0375, Japan
-
Kyushu University Hospital
RECRUITINGFukuoka, 812-8582, Japan
-
Liga Norte-Rio-Grandense Contra o Câncer
RECRUITINGNatal, 59062-000, Brazil
-
Mayo Clinic - Rochester
NOT_YET_RECRUITINGRochester, Minnesota, 55904, United States
-
Mayo Clinic Hospital
NOT_YET_RECRUITINGJacksonville, Florida, 32224, United States
-
Montefiore Medical Center
RECRUITINGThe Bronx, New York, 10461, United States
-
NHO Nagoya Medical Center
RECRUITINGNagoya, 460-0001, Japan
-
National Cancer Center Hospital East
RECRUITINGKashiwa, 277-8577, Japan
-
Pikeville Medical Center
RECRUITINGPikeville, Kentucky, 41501, United States
-
Samsung Medical Center
NOT_YET_RECRUITINGSeoul, 06351, South Korea
-
Sanatorio Allende
NOT_YET_RECRUITINGCórdoba, X5000JHQ, Argentina
-
Seoul National University Hospital
NOT_YET_RECRUITINGSeoul, 110-744, South Korea
-
Severance Hospital, Yonsei University Health System
NOT_YET_RECRUITINGSeoul, 03722, South Korea
-
Shanghai East Hospital
RECRUITINGShanghai, 200120, China
-
Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine
RECRUITINGHangzhou, 242332, China
-
The Catholic University of Korea, St. Vincent'S Hospital
NOT_YET_RECRUITINGSuwon, 16247, South Korea
-
The First Hospital of China Medical University
NOT_YET_RECRUITINGShenyang, 110001, China
-
The First Hospital of Jilin University
NOT_YET_RECRUITINGChangchun, 130021, China
-
Thomas Jefferson University, Sidney Kimmel Cancer Center
RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
-
Tianjin Medical University Cancer Institute & Hospital
RECRUITINGTiyuan, 300060, China
-
University of California San Diego (Ucsd)-Moores Cancer Center
RECRUITINGLa Jolla, California, 92037, United States
-
University of Kentucky Medical Center
RECRUITINGLexington, Kentucky, 40536, United States
-
Valkyrie Clinical Trials
RECRUITINGLos Angeles, California, 90067, United States
-
Virginia Cancer Specialist
RECRUITINGFairfax, Virginia, 22031, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
valemetostat tosylate and pembrolizumab
What this could lead to
If successful, this combination could offer a new first-line treatment option for people with advanced lung cancer that has high PD-L1 levels.
What could go wrong
This is an early-phase trial (1b/2) with only 137 participants, so results may not confirm benefit. Adding valemetostat may increase side effects without improving outcomes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.